On March 17, 2010, a press conference was held at the National Press Club to announce the innovative breast cancer clinical trial, I-SPY 2.
Speakers at the event included:
Dr. Charles A. Sanders, M.D., Chairman of the Board of the Foundation for the National Institutes of Health and Chairman of the Biomarkers Consortium;
Senator Arlen Specter (D-PA);
Congresswoman Jackie Speier (D-CA);
Dr. Anna Barker, Deputy Director of the National Cancer Institute;
Susan Desmond-Hellmann, MD, MPG, Chancellor of the University of California, San Francisco;
Janet Woodcock, MD, Director, FDA Center for Drug Evaluation and Research;
Dr. Laura Esserman, MD, MBA, Director, Carol Franc Buck Breast Care Center at UCSF;
Donald Berry, Ph.D., Professor and Chair, Department of Biostatistics, Division Head, Division of Quantitative Sciences at MD Anderson Cancer Center; and
Jessica Galloway.
The highly anticipated clinical trial is a public-private collaboration of the Foundation for NIH's The Biomarkers Consortium, combining personalized medicine with a novel trial design to develop potentially life saving new breast cancer drugs.
